Kyle Ra
Impact in
- Nephrology top 2%
- Parathyroid Disorders and Treatments
- Hematology top 5%
- Multiple Myeloma Research and Treatments
Papers in ⓘ
-
- Multiple Myeloma Research and Treatments 5
-
- Amyloidosis: Diagnosis, Treatment, Outcomes 2
- Co-authors
- Johnson Wj (1 shared paper)Holland Jf (2 shared papers)Henderson Es (1 shared paper)Kurt Brunner (1 shared paper)S Pavlovsky (1 shared paper)O Glidewell (1 shared paper)Wallace Hj (1 shared paper)BG Durie (1 shared paper)
- Journals
- PubMed (8 papers)
- Partner nations
- United States
In The Last Decade
Kyle Ra
8 papers receiving 927 citations
Hit Papers
Peers
Comparison fields: 5 of 47
- Nephrology 250
- Hematology 209
- Genetics 198
- Molecular Biology 872
- Oncology 225
Countries citing papers authored by Kyle Ra
This map shows the geographic impact of Kyle Ra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle Ra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle Ra more than expected).
Fields of papers citing papers by Kyle Ra
This network shows the impact of papers produced by Kyle Ra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle Ra. The network helps show where Kyle Ra may publish in the future.
Co-authors
The 9 scholars most cited alongside Kyle Ra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Hit paper breakdown → | 1995 | 884 |
| 2 | Dialysis in the treatment of multiple myeloma. | 1980 | 34 |
| 3 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. | 1982 | 22 |
| 4 | Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). | 1976 | 11 |
| 5 | Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma. | 1991 | 11 |
| 6 | Myeloma and related disorders. | 1982 | 6 |
| 7 | Treatment of chain amyloidosis (AL). | 1998 | 2 |
| 8 | Solitary myeloma (solitary plasmacytoma) of bone. | 1967 | 1 |
About Kyle Ra
Kyle Ra is a scholar working on Hematology, Molecular Biology, Genetics, Oncology and Infectious Diseases, having authored 8 papers that have together received 971 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (5 papers), Cancer Treatment and Pharmacology (2 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (2 papers), Dermatological and Skeletal Disorders (1 paper), Pharmacological Effects and Toxicity Studies (1 paper), Poisoning and overdose treatments (1 paper), Fungal Plant Pathogen Control (1 paper) and Myeloproliferative Neoplasms: Diagnosis and Treatment (1 paper). The work is most often cited by research in Nephrology (250 citations), Hematology (209 citations), Genetics (198 citations), Molecular Biology (872 citations) and Oncology (225 citations). Kyle Ra has collaborated with scholars based in United States. Frequent co-authors include Johnson Wj, Holland Jf, Henderson Es, Kurt Brunner, S Pavlovsky, O Glidewell, Wallace Hj, BG Durie and Mario Boccadoro. Their work appears in journals such as PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.